Related references
Note: Only part of the references are listed.Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study
Xue Yang et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
PI3K inhibition sensitizes EGFR wild-type NSCLC cell lines to erlotinib chemotherapy
Xin Zhou et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
Sara Elena Rebuzzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation
Ying Jin et al.
ONCOGENE (2020)
PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting
Gerard Milano
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study
Lei Lei et al.
CANCER SCIENCE (2020)
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations
Diego Kauffmann-Guerrero et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Yi Wang et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort
Hai-bo Shen et al.
CANCER MANAGEMENT AND RESEARCH (2020)
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA
Won Jin Chang et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
Yijia Guo et al.
FRONTIERS IN ONCOLOGY (2020)
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Edith Borcoman et al.
ONCOIMMUNOLOGY (2019)
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Corey J. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
Jacqueline Aredo et al.
LUNG CANCER (2019)
Whole-exome sequencing insights into pulmonary artery sarcoma mimicking pulmonary embolism: a case report and review
Ying Wu et al.
ONCOTARGETS AND THERAPY (2019)
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi et al.
CLINICAL CANCER RESEARCH (2018)
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
Baohui Han et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes
Paul Vanderlaan et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma
Zhengbo Song et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
E. Jonasch et al.
ANNALS OF ONCOLOGY (2017)
Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Zhengbo Song et al.
CANCER MEDICINE (2016)
Share Paper
